Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction therapy in elderly AML patients unfit for standard chemotherapy
ChiCTR-IIR-17011677Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in acute myeloid leukemia (AML) comparing HAG regimen with Decitabine (2 arms). Primary endpoints: Overall Survival and Disease Free Survival. Started Jun 2017; status: recruiting.
02
Drugs
homoharringtonine + cytarabine + granulocyte-colony stimulating factordecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-IIR-17011677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17011677.